May2026– 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation ...

Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, seven-figure revenue stream reflecting increased commercial ...

Engage Biologics Inc. ("Engage"), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company ("Lilly").

Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...

RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

Engage Biologics is developing the Tethosome platform, a non-viral DNA delivery system. ・Engage said its platform addresses major challenges such as immune sensing and efficient cellular delivery.

Earlier this month, a cluster of severe acute respiratory illnesses aboard the Dutch-flagged cruise ship MV Hondius was reported to the World Health Organization (WHO). The infections have since been ...

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting ...

Researchers at King's College London have identified the biological nature and timing of changes in human cortical neurons ...

The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...